Mark Cook

6.5k citations

90 papers · 2.7k indexed · h-index 25

Hematology top 0.5%
- Multiple Myeloma Research and Treatments 44
- Hematopoietic Stem Cell Transplantation 10
Nephrology top 2%
Immunology top 5%
- Immune Cell Function and Interaction 17
- T-cell and B-cell Immunology 13
Genetics top 5%
Transplantation top 5%
Molecular Biology
- Amyloidosis: Diagnosis, Treatment, Outcomes 24
- Protein Degradation and Inhibitors 16
Oncology
- CAR-T cell therapy research 7
- Cancer Treatment and Pharmacology 7

Co-authors: Paul Cockwell Paul Moss Colin A. Hutchison Charles Craddock David Briggs A.R. Bradwell Nelson Leung Robert A. Kyle
Cited by: Hematology Nephrology Immunology
Journals: Blood (20 papers)British Journal of Haematology (5 papers)Journal of Clinical Oncology (5 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Mark Cook

87 papers receiving 2.6k citations

Peers

Countries citing papers authored by Mark Cook

Since Specialization

Citations

This map shows the geographic impact of Mark Cook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Cook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Cook more than expected).

Fields of papers citing papers by Mark Cook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Cook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Cook. The network helps show where Mark Cook may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark Cook, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Cook Line = papers co-authored together Mark Cook links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class–Exposed Relapsed/Refractory Multiple Myeloma Clinical Pharmacokinetics ·Fan Wu,Jian Zhou,C. Bolduan,Madhan Masilamani,Yiming Cheng,Bae Ho Choi,Mark Cook,Julia Piasecki,Manisha Lamba	2025	2
2	MM-493 Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) With Lenalidomide (R) Maintenance Versus R Maintenance Alone in Adult Patients With Newly Diagnosed Multiple Myeloma (NDMM) Who Have Suboptimal Response to Autologous Stem Cell Transplantation (ASCT): Phase 3 KarMMa-9 Trial Clinical Lymphoma Myeloma & Leukemia ·Noopur Raje,Adam D. Cohen,Maria Fernanda Jácome Hernández,Shaji Kumar,Aurore Perrot,Fredrik Schjesvold,Hermann Einsele,Paula Rodríguez‐Otero,Miguel Oswaldo Giler-Zambrano,Carlos Fernández de Larrea,Felix Obaseki-Iheanyachukwu,Anna Truppel-Hartmann,Iliana A. Kesisova,Fan Wu,Xiaobo Zhong,Maitha Khalil Al Hosani,Mihaela Popa,Mark Cook,María-Victoria Mateos	2024	1
3	P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA HemaSphere ·Julia Piasecki,Keyur Desai,Erasmo Catrileo Salazar,Ethan Thompson,James Pratt,Noopur Raje,Krina K. Patel,Marc S. Raab,Mark Cook,Katy L. Simonsen,Mihaela Popa McKiver,Shari M. Kaiser,Nathan Martin	2023	1
4	Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial Blood ·Michel Delforge,Krina K. Patel,Jorge Washington Viteri Velez,Devender Dhanda,Ling Shi,Shien Guo,Thomas S. Marshall,Bertrand Arnulf,Michèle Cavo,Ajay K. Nooka,Salomon Manier,Natalie S. Callander,Sergio Giralt,Hermann Einsele,Sikander Ailawadhi,M. Burden,Mark Cook,Paula Rodríguez‐Otero	2023	2
5	Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study Blood Cancer Journal ·Punit Yadav,Insara Jaffer Sathick,Nelson Leung,Elizabeth E. Brown,Mark Cook,Paul W. Sanders,Paul Cockwell	2020	30
6	High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial The Lancet Haematology ·Colin A. Hutchison,Paul Cockwell,V. V. Moroz,A.R. Bradwell,Umurova Mokhira Askarboy kizi,Julian D. Gillmore,Mark Jesky,Markus Storr,Julie Wessels,Christopher G. Winearls,Katja Weisel,Nils Heyne,Mark Cook	2019	67
7	Successful Renal Outcome in Membranoproliferative Glomerulonephritis Following Treatment of the Underlying Subtle Clone: A Case Report SHILAP Revista de lepidopterología ·Jessica Mann,Paul Cockwell,信男森,Mark Cook,Guy Pratt,Mark T. Drayson,Jennifer H. Pinney	2018	0
8	The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial Trials ·Alina Striha,A. John Ashcroft,Anna Hockaday,David A. Cairns,J P Degorre,Elizabeth. O'Connell,Cathy Williams,John A. Snowden,Mamta Garg,Jamie Cavenagh,Kwee Yong,Mark T. Drayson,Roger G. Owen,Mark Cook,Gordon Cook	2018	5
9	Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma BMC Nephrology ·Punit Yadav,Paul Cockwell,Mark Cook,Jennifer H. Pinney,敬石崎,Petr Lošťák,David A. Cairns,Roger G. Owen,Faith E. Davies,Graham Jackson,J. Anthony Child,Gareth J. Morgan,Mark T. Drayson	2018	25
10	Current Trends of Renal Impairment in Multiple Myeloma Kidney Diseases ·Punit Yadav,Mark Cook,Paul Cockwell	2015	66
11	Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma Biology of Blood and Marrow Transplantation ·Christopher Parrish,Amin Rahemtulla,Jim Cavet,Rachel M. Pearce,Keiren Kirkland,Jungwha Lee,Mark Cook,Keith Wilson,Gordon Cook	2015	6
12	Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant Leukemia Research ·Emmanouil Nikolousis,Stephen Robinson,Sandeep Nagra,Cassandra Brookes,Francesca Kinsella,Sudhir Tauro,Sally Jeffries,Mike Griffiths,Premini Mahendra,Mark Cook,Shankara Paneesha,Richard Lovell,Bhuvan Kishore,Sridhar Chaganti,Ram Malladi,Manoj Raghavan,Paul Moss,D Milligan,Charles Craddock	2013	23
13	Novel approaches for reducing free light chains in patients with myeloma kidney Nature Reviews Nephrology ·Colin A. Hutchison,Joan Bladé,Paul Cockwell,Mark Cook,Mark T. Drayson,Jean-Paul Fermand,Efstathios Kastritis,Robert A. Kyle,Nelson Leung,Sonia Pasquali,Christopher G. Winearls	2012	28
14	KIR and HLA-C Interactions Promote Differential Dendritic Cell Maturation and Is a Major Determinant of Graft Failure following Kidney Transplantation PLoS ONE ·Atanas K. Stefanov,Chandrashekhar A. Kubal,Jason H. Moore,Desley Neil,Mark Cook,Simon Ball,David Briggs,Paul Moss,Paul Cockwell	2011	20
15	CD8+ T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect Haematologica ·Andrew McLarnon,Karen Piper Hanley,Oliver Goodyear,Julie Arrazi,P Mahendra,Mark Cook,Fiona Clark,Guy Pratt,Charles Craddock,Paul Moss	2010	14
16	Single nucleotide polymorphism analysis of the NKG2D ligand cluster on the long arm of chromosome 6: Extensive polymorphisms and evidence of diversity between human populations Human Immunology ·Ayman Antoun,Shirley Jobson,Mark Cook,Christopher A. O’Callaghan,Paul Moss,David Briggs	2010	29
17	Association of killer cell immunoglobulin-like receptors with primary Sjogren's syndrome Lara D. Veeken ·David Lowe,Mark Cook,Simon Bowman,David Briggs,(unknown)	2009	22
18	Ethnic variability in human leukocyte antigen‐E haplotypes Tissue Antigens ·Ayman Antoun,Shirley Jobson,Mark Cook,Paul Moss,David Briggs	2008	26
19	Donor HLA-C Genotype Has a Profound Impact on the Clinical Outcome Following Liver Transplantation American Journal of Transplantation ·Atanas K. Stefanov,Neil H. Spencer,Mark Cook,Bridget Gunson,Mark Hathaway,Jae Doo Lee,Peter Nightingale,Paul Cockwell,Stefan G. Hübscher,David Adams,Paul Moss,David Briggs	2008	49
20	SNP haplotypes and allele frequencies show evidence for disruptive and balancing selection in the human leukocyte receptor complex Immunogenetics ·Paul J. Norman,Mark Cook,B. Sean Carey,Christine V. F. Carrington,David H. Verity,Kamran Hameed,D. Dan Ramdath,Dasnayanee Chandanayingyong,Mark Leppert,I Llassan,R. W. Vaughan	2004	47

About Mark Cook

Mark Cook is a scholar working on Hematology, Transplantation, Immunology, Oncology and Molecular Biology, having authored 90 papers that have together received 2.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (44 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (24 papers), Immune Cell Function and Interaction (17 papers), Protein Degradation and Inhibitors (16 papers), T-cell and B-cell Immunology (13 papers), Hematopoietic Stem Cell Transplantation (10 papers), CAR-T cell therapy research (7 papers) and Cancer Treatment and Pharmacology (7 papers). The work is most often cited by research in Hematology (1.7k citations), Nephrology (306 citations), Immunology (794 citations), Genetics (303 citations) and Transplantation (66 citations). Mark Cook has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Paul Cockwell, Paul Moss, Colin A. Hutchison, Charles Craddock, David Briggs, A.R. Bradwell, Nelson Leung, Robert A. Kyle, Premini Mahendra and Angela Dispenzieri. Their work appears in journals such as Blood, British Journal of Haematology, Journal of Clinical Oncology, Bone Marrow Transplantation and The Lancet Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact